Jury backs Johnson & Johnson in stent patent row with Boston
This article was originally published in Clinica
A district court jury in Delaware has agreed with Johnson & Johnson's Cordis unit that stents made by Boston Scientific infringe its patents. Analysts had seen the ruling as a foregone conclusion, given the outcomes of earlier litigation against Boston Scientific and Medtronic involving one of the patents, the '762 or Palmaz patent covering balloon expandable stents.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.